Xencor to Present Multiple Posters at the SITC Annual Meeting
27 September 2023 - 11:01PM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced three
poster presentations at the 38th Annual Meeting of the Society for
Immunotherapy of Cancer (SITC), being held in San Diego, November
1-5, 2023.
Poster Presentation Details
Clinical Trials in Progress
- Abstract 764, “A Phase 1, first-in-human (FIH), open-label,
dose-finding and expansion study of XmAb808, a B7H3 x CD28
bispecific antibody, in combination with pembrolizumab in patients
with advanced solid tumors”
Preclinical Programs
- Abstract 1060, “Optimally engineered IL18-Fc fusion proteins
balance potency and pharmacokinetics to promote strong anti-tumor
activity”
- Abstract 1193, “Synergistic targeting of multiple activating
pathways with Natural Killer cell Engagers”
Posters will be available in the poster hall and virtually to
registrants of the SITC Annual Meeting, beginning at 9:00 a.m. PT
on Friday, November 3. In the poster hall, odd-numbered posters
will be displayed on Friday, November 3, and even-numbered posters
will be displayed on Saturday, November 4. Posters will be archived
under “Events & Presentations” in the Investors section of the
Company’s website located at www.xencor.com.
About XmAb®808 (B7-H3 x CD28)
Xencor is conducting a Phase 1 study of XmAb808 in patients with
advanced solid tumors. XmAb808 is a tumor-selective, co-stimulatory
XmAb 2+1 bispecific antibody designed to bind to the broadly
expressed tumor antigen B7-H3 and selectively to the CD28 T-cell
co-receptor only when bound to tumor cells, which was demonstrated
in in vitro studies. Strong potentiation of checkpoint and CD3
cytotoxic activity was also observed in vivo. XmAb808 is a wholly
owned Xencor program.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact. Such
statements are made on the basis of the current beliefs,
expectations, and assumptions of the management of Xencor and are
subject to significant known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements and the timing of events to be materially different
from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance
or results. Such risks include, without limitation, the risks
associated with the process of discovering, developing,
manufacturing and commercializing drugs that are safe and effective
for use as human therapeutics and other risks, including the
ability of publicly disclosed clinical trial design to support
continued clinical development and regulatory approval for specific
treatments, in each case as described in Xencor's public securities
filings. For a discussion of these and other factors, please refer
to Xencor's annual report on Form 10-K for the year ended December
31, 2022 as well as Xencor's subsequent filings with the Securities
and Exchange Commission. You are cautioned not to place undue
reliance on forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, as amended
to date. All forward-looking statements are qualified in their
entirety by this cautionary statement and Xencor undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230927601263/en/
Charles Liles cliles@xencor.com 626-737-8118
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Apr 2024 to May 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From May 2023 to May 2024